Literature DB >> 14610107

Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

Andrew R Pachner1, Antonio Bertolotto, Florian Deisenhammer.   

Abstract

Myxovirus A (MxA) is a protein that is specifically induced by treatment with type I cytokines and has proven to be a reliable biomarker of interferon-beta (IFNbeta) bioactivity. IFNbeta-induced MxA can be measured as either protein or mRNA in the blood of IFNbeta-treated patients with MS. In patients with MS who are treated with IFNbeta, loss of the MxA response is caused by high levels of anti-IFNbeta antibodies and is a sensitive marker of lost bioactivity.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14610107     DOI： 10.1212/01.wnl.0000092361.04511.d0

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  15 in total

1.  Neutralizing antibodies against interferon-Beta.

Authors:  Per Soelberg Sorensen
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

2.  Expression of biomarkers of interferon type I in patients suffering from chronic diseases.

Authors:  C Scagnolari; F Bellomi; S Trombetti; M Casato; M Carlesimo; F Bagnato; V Lavolpe; R Bruno; E Millefiorini; L Antonelli; E Girardi; O Turriziani; G Antonelli
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

3.  Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients.

Authors:  Andrew R Pachner; Jennifer Brady; Israel Steiner; Kavitha Narayan
Journal:  J Neurol       Date:  2008-11-22       Impact factor: 4.849

Review 4.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

5.  Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats.

Authors:  Ekaterina V Medvedeva; Veronika G Dmitrieva; Svetlana A Limborska; Nikolay F Myasoedov; Lyudmila V Dergunova
Journal:  Mol Genet Genomics       Date:  2017-03-02       Impact factor: 3.291

6.  Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

Authors:  A Bertolotto; A Sala; S Malucchi; F Marnetto; M Caldano; A Di Sapio; M Capobianco; F Gilli
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-09       Impact factor: 10.154

7.  Oral delivery of oligomeric procyanidins in Apple Poly® enhances type I IFN responses in vivo.

Authors:  Deann T Snyder; Amanda Robison; Sharon Kemoli; Emily Kimmel; Jeff Holderness; Mark A Jutila; Jodi F Hedges
Journal:  J Leukoc Biol       Date:  2014-01-13       Impact factor: 4.962

8.  Identification of human metapneumovirus-induced gene networks in airway epithelial cells by microarray analysis.

Authors:  X Bao; M Sinha; T Liu; C Hong; B A Luxon; R P Garofalo; A Casola
Journal:  Virology       Date:  2008-01-29       Impact factor: 3.616

9.  Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patients.

Authors:  Marta Garcia-Montojo; Virginia De Las Heras; Manuel Bartolome; Rafael Arroyo; Roberto Alvarez-Lafuente
Journal:  J Neurovirol       Date:  2007-12       Impact factor: 2.643

10.  Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.

Authors:  Emilia Sbardella; Valentina Tomassini; Claudio Gasperini; Francesca Bellomi; Luca Ausili Cefaro; Vincenzo Brescia Morra; Guido Antonelli; Carlo Pozzilli
Journal:  BMC Neurol       Date:  2009-10-13       Impact factor: 2.474
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.